Video webcast now available on-demandBOSTON and LONDON, July 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: ...

Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in ...

Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to ...

Fintel reports that on July 18, 2025, Maxim Group initiated coverage of Akari Therapeutics, Plc - Depositary Receipt () ...

Akari Therapeutics, a biotechnology company focused on developing precision bi-functional antibody drug conjugates (ADCs) for cancer treatment, announced its participation in the Virtual Investor ...

Maxim analyst Jason McCarthy initiated coverage of Akari Therapeutics (AKTX) with a Buy rating and $5 price target Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! ...

Video webcasts from participating companies now available here FRENCHTOWN, NJ / ACCESS Newswire / July 22, 2025 / JTC Team ...

On March 5, 2024, Akari and Peak Bio announced a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, Plc, which is expected ...

BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory ...

Akari Therapeutics Plc (Nasdaq: AKTX) is dedicated to developing advanced therapies for autoimmune and inflammatory diseases. The company's lead asset, investigational nomacopan, ...

Dec 5 (Reuters) - Akari Therapeutics Plc. Skip to main content. Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv. Reuters home. World. Browse World.

--Akari Therapeutics, Plc and Peak Bio Inc. today announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously ...